This report was our free report of the day on a previous date — it has since expired.
Today's free report is available: MU 10-K — Micron revenue triples to $133.2B on AI demand; operating income hits $99.3B
Get notified when OLMA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOlema's net loss widened to $63.2M in the second quarter from $43.8M a year earlier.
Filed August 10, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 11, 2025 · ~1 min read
Key Changes
-
high
Research and development expenses rose 31.6% to $57.8M in the quarter, which the company attributes to the continued execution of our clinical development strategy, including ongoing activities supporting our pivotal Phase 3 OPERA-01 and OPERA-02 trials for palazestrant, continued advancement of our Phase 1 OP-3136 clinical program, and increased manufacturing and clinical supply activities supporting these programs.
-
medium
General and administrative expenses increased 137.1% to $9.4M, primarily due to higher non-cash stock-based compensation of $3.0 million associated with equity awards granted at higher market prices, and increased professional fees of $1.8 million.
-
high
Cash, cash equivalents and marketable securities totaled $461.1M at June 30, 2026, which the company expects will fund operations through mid-2028.
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Partner
Trade OLMA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 11, 2026 · How we verify